Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 VENUS REMEDIES   ACTAVIS
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-23
ACTAVIS
Dec-18
VENUS REMEDIES/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs37916,126-   
Low Rs14510,818-   
Sales per share (Unadj.) Rs415.53,955.8-  
Earnings per share (Unadj.) Rs19.9-1,274.2-  
Cash flow per share (Unadj.) Rs44.0416.9-  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs344.316,315.7-  
Shares outstanding (eoy) m13.37332.60-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x0.63.4 18.5%   
Avg P/E ratio x13.2-10.6 -124.7%  
P/CF ratio (eoy) x5.932.3 18.4%  
Price / Book Value ratio x0.80.8 92.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m3,5014,480,758 0.1%   
No. of employees `000NA16.9 0.0%   
Total wages/salary Rs m5700-   
Avg. sales/employee Rs Th077,851.4-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0-25,076.0-  
INCOME DATA
Net Sales Rs m5,5551,315,689 0.4%  
Other income Rs m10325,160 0.4%   
Total revenues Rs m5,6581,340,849 0.4%   
Gross profit Rs m60234,478 1.7%  
Depreciation Rs m323562,428 0.1%   
Interest Rs m375,923 0.0%   
Profit before tax Rs m379-578,713 -0.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0147,595 0.0%   
Tax Rs m114-7,334 -1.5%   
Profit after tax Rs m266-423,784 -0.1%  
Gross profit margin %10.82.6 413.5%  
Effective tax rate %30.01.3 2,364.3%   
Net profit margin %4.8-32.2 -14.8%  
BALANCE SHEET DATA
Current assets Rs m3,230539,627 0.6%   
Current liabilities Rs m826477,372 0.2%   
Net working cap to sales %43.34.7 914.5%  
Current ratio x3.91.1 346.0%  
Inventory Days Days3720 188.6%  
Debtors Days Days50466 759.6%  
Net fixed assets Rs m2,781148,929 1.9%   
Share capital Rs m1340-   
"Free" reserves Rs m4,4700-   
Net worth Rs m4,6035,426,601 0.1%   
Long term debt Rs m3871,910,903 0.0%   
Total assets Rs m6,0118,483,012 0.1%  
Interest coverage x130.0-6.6 -1,963.3%   
Debt to equity ratio x0.10.4 23.9%  
Sales to assets ratio x0.90.2 595.9%   
Return on assets %4.5-4.1 -109.0%  
Return on equity %5.8-7.8 -73.9%  
Return on capital %7.7-4.8 -158.2%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m00-   
CASH FLOW
From Operations Rs m366470,046 0.1%  
From Investments Rs m-508258,229 -0.2%  
From Financial Activity Rs m-6-806,740 0.0%  
Net Cashflow Rs m-220-78,073 0.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 83.34 Rs / USD

Compare VENUS REMEDIES With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare VENUS REMEDIES With: DISHMAN PHARMA  ANUH PHARMA  UNICHEM LAB  BERYL DRUGS  GRANULES INDIA  



Today's Market

Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising(Closing)

After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.